华润双鹤：地诺孕素片获俄罗斯药品注册证书

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, China Resources Zizhu Pharmaceutical Co., Ltd., has received a drug registration certificate from the Ministry of Health of the Russian Federation for Dienogest tablets, which are used to treat endometriosis [1] Group 1: Drug Registration and Market Entry - The registration process for Dienogest tablets began in September 2022, with the market approval application submitted in March 2024 [1] - The drug has a global sales figure of USD 365 million in 2023 [1] Group 2: Domestic Sales and Market Share - In 2024, the domestic sales total for Dienogest tablets is projected to be CNY 790 million, with Jenapharm holding a market share of 87.18% and Shanghai Huilun Jiangsu Pharmaceutical accounting for 9.32% [1] - The expected sales revenue for the company from this drug in 2024 is CNY 42.7649 million, with no sales established in Russia as of the announcement date [1] Group 3: Research and Development Investment - The research and development investment for the drug amounts to CNY 189,000 [1]